insulin detemir vs Insulin glargine (Basaglar)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
insulin detemir · Levemir
Rights held by Novo Nordisk; US product discontinued
NCT00283751 · Phase 3 · completed
The study randomized 583 participants to insulin detemir or insulin glargine, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07) (met)
Result source: NCT00856986
Insulin glargine (Basaglar)
Marketed by Eli Lilly and partners
NCT01421459 · Phase 3 · completed
The study was randomized, triple-blind, and active-controlled, with 759 participants, but its primary endpoint was HbA1c, a laboratory surrogate rather than a hard clinical outcome. The prespecified non-inferiority comparison was met: the 95% confidence interval for the treatment difference remained below the +0.4% margin.
Reported efficacy
Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062) (met)
Result source: NCT03338010
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | insulin detemir | Insulin glargine (Basaglar) |
|---|---|---|
| HbA1c, change | -0.5% vs 0.0%vs Lira 1.8NCT008569866 other results
| -1.3% vs -1.3%vs LantusNCT014214599 other results
|
| Body weight, change (kg) | 3.6 vs 6.4vs Insulin AspartNCT001846008 other results
| 1.9 vs 2.2vs LantusNCT014214597 other results
|
| HbA1c below 7% | —Not posted · NCT00604396 | 43.7% vs 44.9%vs Lantus®NCT03338010 |
| Fasting plasma glucose, change | -1.9 vs -0.1vs Lira 1.8NCT008569862 other results
| —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT00604396 | —Not reported |
HbA1c, change
- insulin detemir
- -0.5% vs 0.0%vs Lira 1.8NCT00856986
6 other results
- -0.5% vs -0.1% NCT00856986
- -0.5% vs 0.0% NCT00856986
- -1.0% vs -1.1% NCT01165684
- -0.5% vs -0.7% NCT00909480
- -0.8% vs -1.1% NCT01165684
- -0.5% vs -1% NCT01165684
- Insulin glargine (Basaglar)
- -1.3% vs -1.3%vs LantusNCT01421459
9 other results
- -1.3% vs -1.2% NCT02302716
- -1.3% vs -1.2% NCT03338010
- -1.3% vs -1.4% NCT01421459
- -1.3% vs -1.2% NCT03338010
- -1.3% vs -1.4% NCT01421459
- -1.3% vs -1.3% NCT01421459
- -1.1% vs -1.1% NCT01421459
- -0.9% vs -0.9% NCT01421459
- -0.5% vs -0.5% NCT01421459
Body weight, change (kg)
- insulin detemir
- 3.6 vs 6.4vs Insulin AspartNCT00184600
8 other results
- -0.1 vs -1.0 NCT00856986
- 1.9 vs 5.7 NCT00184600
- -0.2 vs -0.9 NCT00856986
- -0.8 vs -1.7 NCT00789191
- -0.5 vs 1 NCT00909480
- 0.3 vs 0.8 NCT00998335
- 13 vs 12.6 NCT01837680
- 1.2 vs 2.8 NCT00604396
- Insulin glargine (Basaglar)
- 1.9 vs 2.2vs LantusNCT01421459
7 other results
- 2.3 vs 1.7 NCT02302716
- 1.1 vs 1.2 NCT03338010
- 1.7 vs 2.2 NCT01421459
- 1.6 vs 1.9 NCT01421459
- 1.3 vs 1.4 NCT01421459
- 1.0 vs 1.2 NCT01421459
- 0.3 vs 0.5 NCT01421459
HbA1c below 7%
- insulin detemir
- —Not posted · NCT00604396
- Insulin glargine (Basaglar)
- 43.7% vs 44.9%vs Lantus®NCT03338010
Fasting plasma glucose, change
- insulin detemir
- -1.9 vs -0.1vs Lira 1.8NCT00856986
2 other results
- -2.1 vs -0.4 NCT00856986
- 6.4 vs 4.9 NCT00998335
- Insulin glargine (Basaglar)
- —Not reported
3-point MACE (% with event)
- insulin detemir
- —Not posted · NCT00604396
- Insulin glargine (Basaglar)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. insulin detemir: 6 of 6 rows · Insulin glargine (Basaglar): 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | insulin detemir Rows use multiple source trials | Insulin glargine (Basaglar) Rows use multiple source trials |
|---|---|---|
| HbA1c absolute change · percentage points No placebo or comparator arm | -0.9% (n=21) @ 12wka,b,c NCT01868542 · Phase 4 · registry result, not featured evidence show 1 more dose-0.8% (n=23) @ 12wk NCT01868542 · Phase 4 · registry result, not featured evidence | -0.641% (n=259) @ 12wkb,c NCT04153981 · Phase 4 · registry result, not featured evidence |
| HbA1c Less Than or Equal to 6.5 responder rate · % of participants | 43.2% (n=234) vs 44.8% (n=239) Insulin Aspart @ 156wkb,c,d NCT00184600 · Phase 3 · registry result, not featured evidence | 23.4% (n=334) vs 16.5% (n=158) Lantus® @ 24wkb,c,d NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 |
| Dropout rate | 0%e NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results8.7%Insulin Detemir (2-4-6-8 Algorithm NCT01868542 · Phase 4 · registry result, not featured evidence 0%Insulin Detemir (3-0-3 Algorithm ) NCT01868542 · Phase 4 · registry result, not featured evidence 13.9% NCT01165684 · Phase 4 · registry result, not featured evidence 16.7% NCT00909480 · Phase 4 · registry result, not featured evidence — NCT00998335 · Phase 4 · registry result, not featured evidence · combination 0% NCT00591227 · Phase 4 · registry result, not featured evidence 6.9% NCT00455858 · Phase 4 · registry result, not featured evidence 12.3%FPG 70-90 mg/dL NCT00634842 · Phase 4 · registry result, not featured evidence 14.8%FPG 80-110 mg/dL NCT00634842 · Phase 4 · registry result, not featured evidence — NCT00467649 · Phase 4 · registry result, not featured evidence · combination 0% NCT00590226 · Phase 4 · registry result, not featured evidence · combination 19.2% NCT00184600 · Phase 3 · registry result, not featured evidence 12.6% NCT00789191 · Phase 3 · registry result, not featured evidence · combination 0%Iiraglutide NCT01232946 · Phase na · registry result, not featured evidence 18.2%Liraglutide Plus Insulin Detemir NCT01232946 · Phase na · registry result, not featured evidence · combination 15.1% NCT01837680 · Phase na · registry result, not featured evidence | 11.9%f NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more results7.6% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.4% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 28.3% NCT04153981 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | 0%e NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results—Insulin Detemir (2-4-6-8 Algorithm NCT01868542 · Phase 4 · registry result, not featured evidence —Insulin Detemir (3-0-3 Algorithm ) NCT01868542 · Phase 4 · registry result, not featured evidence 0.5% NCT01165684 · Phase 4 · registry result, not featured evidence 2.2% NCT00909480 · Phase 4 · registry result, not featured evidence — NCT00998335 · Phase 4 · registry result, not featured evidence · combination — NCT00591227 · Phase 4 · registry result, not featured evidence — NCT00455858 · Phase 4 · registry result, not featured evidence 1.6%FPG 70-90 mg/dL NCT00634842 · Phase 4 · registry result, not featured evidence 2.5%FPG 80-110 mg/dL NCT00634842 · Phase 4 · registry result, not featured evidence — NCT00467649 · Phase 4 · registry result, not featured evidence · combination — NCT00590226 · Phase 4 · registry result, not featured evidence · combination 3.8% NCT00184600 · Phase 3 · registry result, not featured evidence 1.8% NCT00789191 · Phase 3 · registry result, not featured evidence · combination —Iiraglutide NCT01232946 · Phase na · registry result, not featured evidence —Liraglutide Plus Insulin Detemir NCT01232946 · Phase na · registry result, not featured evidence · combination — NCT01837680 · Phase na · registry result, not featured evidence | 1.6%f NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more results0.4% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.8% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 — NCT04153981 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 10.4%e NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results4.3%Insulin Detemir (2-4-6-8 Algorithm NCT01868542 · Phase 4 · registry result, not featured evidence 0%Insulin Detemir (3-0-3 Algorithm ) NCT01868542 · Phase 4 · registry result, not featured evidence 9.1% NCT01165684 · Phase 4 · registry result, not featured evidence 3.1% NCT00909480 · Phase 4 · registry result, not featured evidence 0% NCT00998335 · Phase 4 · registry result, not featured evidence · combination 0% NCT00591227 · Phase 4 · registry result, not featured evidence 5.7% NCT00455858 · Phase 4 · registry result, not featured evidence 4.1%FPG 70-90 mg/dL NCT00634842 · Phase 4 · registry result, not featured evidence 3.3%FPG 80-110 mg/dL NCT00634842 · Phase 4 · registry result, not featured evidence 0% NCT00467649 · Phase 4 · registry result, not featured evidence · combination 22.4% NCT00590226 · Phase 4 · registry result, not featured evidence · combination 33.3% NCT00184600 · Phase 3 · registry result, not featured evidence 1.9% NCT00789191 · Phase 3 · registry result, not featured evidence · combination 0%Iiraglutide NCT01232946 · Phase na · registry result, not featured evidence 0%Liraglutide Plus Insulin Detemir NCT01232946 · Phase na · registry result, not featured evidence · combination 0% NCT01837680 · Phase na · registry result, not featured evidence | 4%f NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more results4% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.8% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | e nasopharyngitis 20.2% nausea 18.4% diarrhoea 17.8% NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 13 more resultsnasopharyngitis 13% headache 8.7% upper respiratory tract infection 4.3% NCT01868542 · Phase 4 · registry result, not featured evidence nasopharyngitis 13% rash 8.7% upper respiratory tract infection 8.7% NCT01868542 · Phase 4 · registry result, not featured evidence nasopharyngitis 8.1% headache 5.1% influenza 5.1% NCT01165684 · Phase 4 · registry result, not featured evidence nasopharyngitis 10.6% upper respiratory tract infection 8% headache 7.5% NCT00909480 · Phase 4 · registry result, not featured evidence nasopharyngitis 11.5% upper respiratory tract infection 5.7% NCT00455858 · Phase 4 · registry result, not featured evidence back pain 5.8% headache 5% upper respiratory tract infection 5% NCT00634842 · Phase 4 · registry result, not featured evidence pain in extremity 3.3% urinary tract infection 3.3% anxiety 2.5% NCT00634842 · Phase 4 · registry result, not featured evidence nausea 11.1% diarrhoea 5.6% hypertension 5.6% NCT00467649 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 46.2% diarrhoea 25.6% infection 21.4% NCT00184600 · Phase 3 · registry result, not featured evidence headache 14.5% nasopharyngitis 13.2% back pain 10.5% NCT00789191 · Phase 3 · registry result, not featured evidence · combination gastrointestinal intolerance 0% NCT01232946 · Phase na · registry result, not featured evidence gastrointestinal intolerance 18.2% NCT01232946 · Phase na · registry result, not featured evidence · combination biochemical event of hypoglycemia 50.9% symptomatic hypoglycemia 30.2% symptomatic nocturnal event 15.1% NCT01837680 · Phase na · registry result, not featured evidence | f nasopharyngitis 5.6% upper respiratory tract infection 5.1% abnormal weight gain 2.7% NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more resultsnasopharyngitis 7.2% upper respiratory tract infection 4% weight increased 3.2% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 upper respiratory tract infection 20.3% hypertension 5.6% injection site pain 4.2% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 anaemia 1.9% cough 0.4% hyperglycaemia 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 156 weeks versus 24 weeks.
- ePopulation comparability has not been reviewed for 16 of these studies.
- fPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
insulin detemir
show 3 more results
show 3 more results
show 2 more results
show 5 more results
show 2 more results
+ 32 further endpoints in the CSV export.
Insulin glargine (Basaglar)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin detemir's landscape · Insulin glargine (Basaglar)'s landscape